Jillian E Halladay1, Catharine Munn1,2, Michael Boyle1,2,3, Susan M Jack1,3,4, Katholiki Georgiades1,2,3. 1. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario. 2. Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton Ontario. 3. Offord Centre for Child Studies, McMaster University, Hamilton, Ontario. 4. School of Nursing, McMaster University, Hamilton, Ontario.
Abstract
BACKGROUND: With the recent legalization of nonmedical cannabis in Canada, it is important to document previous associations between cannabis use and major depressive episode and suicidal ideation, as well as the extent to which these associations have changed over time. METHODS: This study uses pooled data from the 2002 and 2012 Canadian Community Health Survey's Mental Health Component, which are repeated cross-sectional surveys of nationally representative samples of Canadians 15 to 60 years of age (n = 43,466). Binary logistic regression was performed, applying weighting and bootstrapping, to examine the association between at least monthly use of cannabis and past 12-month suicidal ideation and major depressive episode (MDE). RESULTS: At least monthly nonmedical cannabis use was associated with an increased odds of MDE and suicidal ideation, and both associations strengthened in 2012 compared to 2002. Canadians using cannabis at least once a month in 2012 had 1.59 (95% confidence interval [CI], 1.11 to 2.27) times the odds of experiencing suicidal ideation and 1.55 (95% CI, 1.12 to 2.13) times the odds of experiencing MDE compared to those who used cannabis at least once a month in 2002. This temporal change remained after controlling for other substance use. CONCLUSIONS: Monthly cannabis use was consistently related to both suicidal ideation and MDE, and these associations were stronger in 2012 compared to 2002. The findings of this study provide a baseline for the association between cannabis use and suicide and depression in the Canadian population that should be reevaluated now that nonmedical cannabis has been legalized.
BACKGROUND: With the recent legalization of nonmedical cannabis in Canada, it is important to document previous associations between cannabis use and major depressive episode and suicidal ideation, as well as the extent to which these associations have changed over time. METHODS: This study uses pooled data from the 2002 and 2012 Canadian Community Health Survey's Mental Health Component, which are repeated cross-sectional surveys of nationally representative samples of Canadians 15 to 60 years of age (n = 43,466). Binary logistic regression was performed, applying weighting and bootstrapping, to examine the association between at least monthly use of cannabis and past 12-month suicidal ideation and major depressive episode (MDE). RESULTS: At least monthly nonmedical cannabis use was associated with an increased odds of MDE and suicidal ideation, and both associations strengthened in 2012 compared to 2002. Canadians using cannabis at least once a month in 2012 had 1.59 (95% confidence interval [CI], 1.11 to 2.27) times the odds of experiencing suicidal ideation and 1.55 (95% CI, 1.12 to 2.13) times the odds of experiencing MDE compared to those who used cannabis at least once a month in 2002. This temporal change remained after controlling for other substance use. CONCLUSIONS: Monthly cannabis use was consistently related to both suicidal ideation and MDE, and these associations were stronger in 2012 compared to 2002. The findings of this study provide a baseline for the association between cannabis use and suicide and depression in the Canadian population that should be reevaluated now that nonmedical cannabis has been legalized.
Entities:
Keywords:
cannabis use disorders; epidemiology; general population; major depressive disorder; substance use disorders; suicide
Authors: Mahmoud A ElSohly; Zlatko Mehmedic; Susan Foster; Chandrani Gon; Suman Chandra; James C Church Journal: Biol Psychiatry Date: 2016-01-19 Impact factor: 13.382
Authors: Jennifer McNeely; Charles M Cleland; Shiela M Strauss; Joseph J Palamar; John Rotrosen; Richard Saitz Journal: J Gen Intern Med Date: 2015-05-19 Impact factor: 5.128
Authors: Toby T Winton-Brown; Paul Allen; Sagnik Bhattacharyya; Sagnik Bhattacharrya; Stefan J Borgwardt; Paolo Fusar-Poli; Jose A Crippa; Marc L Seal; Rocio Martin-Santos; Dominic Ffytche; Antonio W Zuardi; Zerrin Atakan; Philip K McGuire Journal: Neuropsychopharmacology Date: 2011-03-16 Impact factor: 7.853
Authors: Chandni Hindocha; Tom P Freeman; Grainne Schafer; Chelsea Gardener; Ravi K Das; Celia J A Morgan; H Valerie Curran Journal: Eur Neuropsychopharmacol Date: 2014-12-05 Impact factor: 4.600
Authors: R Martin-Santos; J A Crippa; A Batalla; S Bhattacharyya; Z Atakan; S Borgwardt; P Allen; M Seal; K Langohr; M Farré; A W Zuardi; P K McGuire Journal: Curr Pharm Des Date: 2012 Impact factor: 3.116